158P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic NSCLC (mNSCLC): Pharmacokinetics (PK) and anti-drug antibody (ADA) data from the phase III POSEIDON trial

Immuno-oncology drugs have the potential to induce ADAs and neutralizing ADAs (nAbs). Although ADAs may be associated with altered drug PK and adverse effects (AEs), the clinical impact is not well defined. Using data from POSEIDON (NCT03164616) we evaluated the PK and immunogenicity of D and T and assessed the potential impact of ADAs on PK and safety.